WO2022114077A1 - Composition d'amélioration de la peau - Google Patents

Composition d'amélioration de la peau Download PDF

Info

Publication number
WO2022114077A1
WO2022114077A1 PCT/JP2021/043262 JP2021043262W WO2022114077A1 WO 2022114077 A1 WO2022114077 A1 WO 2022114077A1 JP 2021043262 W JP2021043262 W JP 2021043262W WO 2022114077 A1 WO2022114077 A1 WO 2022114077A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
isoflavone
isoflavones
improvement
lactobionic acid
Prior art date
Application number
PCT/JP2021/043262
Other languages
English (en)
Japanese (ja)
Inventor
健一 大江
裕一 卯川
利雄 鈴木
俊也 丸尾
彩加 川端
良太 赤木
Original Assignee
株式会社ダイセル
フジッコ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社ダイセル, フジッコ株式会社 filed Critical 株式会社ダイセル
Priority to JP2022538321A priority Critical patent/JP7159511B1/ja
Publication of WO2022114077A1 publication Critical patent/WO2022114077A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This disclosure relates to a composition for improving skin.
  • Patent Documents It has long been known that isoflavones (particularly isoflavone aglycones such as genistein and daidzein) have the effects of promoting hyaluronic acid production in the skin, improving collagen metabolism, and improving rough skin. 1). For example, in a clinical trial of 26 women in their 30s and 40s, it has been reported that oral intake of 40 mg of isoflavone aglycone daily for 3 months promotes collagen production and reduces the area of wrinkles (non-). Patent Document 1).
  • lactobionic acid (4-O- ⁇ -galactopyranosyl-D-gluconic acid) is an acidic oligosaccharide obtained by oxidizing lactose.
  • Lactobionic acid is expected to stabilize the lamellar structure, which has a moisturizing function in the skin structure, and to have a moisturizing effect and a skin protective effect (Non-Patent Document 2).
  • Non-Patent Document 2 it has been reported that when calcium lactobionate is administered to rats, the plasma equol concentration is significantly increased (Patent Document 2).
  • Patent Document 2 it is not known that the combined use of isoflavone glycosides and / or isoflavone aglycones and lactobionic acid improves the skin more than when each is taken alone.
  • the subject of this disclosure is at least the provision of technology to improve the skin.
  • the present inventors have found that the above-mentioned problems can be solved by ingesting isoflavone glycosides and / or isoflavone aglycones and lactobionic acid in combination.
  • the present disclosure can provide skin-improving compositions comprising isoflavone glycosides and / or isoflavone aglycones and lactobionic acid.
  • the daily intake of the glycosides of the isoflavones and / or the aglycones of the isoflavones is 20 mg or more and less than 30 mg in terms of aglycone as a total amount, and the daily intake of the lactobionic acid is A preferred embodiment is 200 mg or more.
  • the composition is also preferably a food or drink.
  • This disclosure can at least have the effect of providing a technique for improving the skin.
  • composition containing isoflavone glycosides and / or isoflavone aglycones and lactobionic acid.
  • the composition may be referred to as "composition according to this embodiment" or the like.
  • composition according to this embodiment may contain only isoflavone glycosides and / or isoflavone aglycones and lactobionic acid, and other as long as the skin is improved in the subject ingesting it. It may contain an ingredient.
  • the target for ingesting the composition according to this embodiment is a human, preferably a human who seeks improvement of the skin.
  • the person may be male or female.
  • the improvement of the skin means that the subject has more isoflavones than when the subject does not take isoflavone glycosides and / or isoflavones aglycone and lactobionic acid in combination (or when he / she takes placebo). It is said that the skin is improved when the glycosides and / or the isoflavones aglycone and lactobionic acid are taken in combination.
  • Examples of skin improvement include improvement of keratin water content (for example, suppression of decrease in keratin water content, increase, etc.), and skin improvement caused by improvement of keratin water content, for example, skin moisturizing property. Improvement of skin, improvement of flexibility, improvement of texture, improvement of skin barrier function, improvement of wrinkles.
  • the keratin water content can be measured, for example, by measuring the capacitance on the skin surface using a Corneometer (registered trademark) CM825 (Courage + Khazaka electronic GmbH).
  • Examples of skin improvement include improvement of transepidermal water loss (TransEpidermal Water Loss, TEWL) (for example, suppression of increase or decrease of TEWL), and improvement of skin caused by improvement of TEWL.
  • TEWL Transepidermal Water Loss
  • improvement of skin moisturizing property, improvement of flexibility, improvement of texture, improvement of skin barrier function, improvement of wrinkles can be mentioned.
  • Tewameter registered trademark
  • TM300 Cosmetic + Khazakaelectronic GmbH
  • examples of skin improvement include improvement of skin viscoelasticity
  • examples of skin improvement resulting from improvement of skin viscoelasticity include improvement of skin flexibility.
  • the improvement of skin viscoelasticity can be judged by focusing on, for example, net elasticity (R5), total elasticity (R2), return rate (R7), unrecovered extensibility / involution ability (R1), and the like. Since the net elasticity (R5), total elasticity (R2), and return rate (R7) are values that decrease with aging, it is judged that the decrease was suppressed or the value was improved by increasing the value. be able to.
  • the unrecovered extensibility / regression ability (R1) is a value that increases with aging, it can be judged that the value is improved by suppressing the increase in the value or decreasing the value.
  • the skin viscoelasticity can be measured, for example, using a Cutometer® MPA580 (Courage + Khazaka electronic GmbH, probe diameter 2 mm).
  • skin improvement for example, improvement of concern about pores, improvement of rough texture, improvement of rough skin, improvement of concern about stains and freckles are improved.
  • the complexion is improved, the skin is not transparent, the skin is dull, the skin is dry, and the fine wrinkles on the outer corners of the eyes are worrisome.
  • Improvement improvement of sagging under the eyes, improvement of firmness and dullness, improvement of lack of fluffy skin, improvement of easy loss of makeup, bad makeup It improves things, it improves skin condition, it improves that the face is greasy, it improves that it is easy to get acne, and it improves skin itching (itching of the skin). To do. These can be judged, for example, based on the results of a skin condition questionnaire conducted with a subject trained so as to be able to perform an objective evaluation as a panelist.
  • Isoflavones are one of the classifications of polyphenols, and are flavonoids having isoflavones as the basic skeleton. In general, isoflavones, in a broad sense, thus refer to flavonoids having isoflavones as a basic skeleton. The isoflavones of the present disclosure are also defined as this. Isoflavones are abundant in legumes such as soybeans, kudzu, red clover, and licorice.
  • isoflavones in this embodiment include isoflavones derived from legumes including isoflavones, and specifically, isoflavones derived from soybeans (in the technical field and the market, "soy isoflavones” and “soybeans”). It may be referred to as “isoflavones”, etc., and is treated as synonymous in this disclosure), isoflavones derived from kudzu (in the relevant technical field and market, it is referred to as “kuzu isoflavone”, “kuzu isoflavone”, etc.
  • Isoflavones derived from red clover may be referred to as “red clover isoflavones” or “red clover isoflavones” in the relevant technical field and market, and are treated as synonymous in this disclosure.
  • Isoflavones derived from can elephants which may be referred to as “canzo isoflavones” or “canzo isoflavones” in the art and the market, and are treated as synonyms in the present disclosure).
  • glycosides of the isoflavones include genistin, glycitin, daidzin, puerarin and the like, and in the composition according to this embodiment, two or more mixtures may be used. For example, it may be a mixture of daidin, glycitin, and genistin.
  • the isoflavone aglycones include daidzein, 6-hydroxydaidzein, dihydroxydaidzein, genistein, glycitein, biochanin A, formonetin, coumestrol, and the like, and in the composition according to this embodiment, two or more. May be a mixture of.
  • the isoflavone aglycone may be an isoflavone converted by an enzyme such as ⁇ -glucosidase or a microorganism having ⁇ -glucosidase.
  • the term "isoflavone aglycone" in the present disclosure may be referred to as "isoflavone aglycone" in the technical field and market, and is treated as a synonym in the present disclosure.
  • Lactobionic acid is a disaccharide and sugar acid consisting of gluconic acid and galactose. Lactobionic acid may also be described as 4-O- ⁇ -galactopyranosyl-D-gluconic acid. Lactobionic acid causes microorganisms having lactose-oxidizing activity such as Acinetobacter, Burghorderia, Acetobacter, and Gluconobacter to act on lactose, which is a raw material, to oxidize lactose and produce a supernatant. It is known to be obtained by recovery. Details are described in JP-A-2001-245657, JP-A-2007-288917, and the like.
  • the total amount of isoflavone glycosides and / or isoflavone aglycones is preferably 0.001% by weight or more, more preferably 0.01% by weight or more, based on the total amount of the composition according to this embodiment. Yes, more preferably 0.1% by weight or more, while preferably 50% by weight or less, more preferably 40% by weight or less, still more preferably 10% by weight or less. Moreover, it may be a consistent combination thereof.
  • the content of lactobionic acid with respect to the total amount of the composition according to this embodiment is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, still more preferably 1% by weight or more, and on the other hand. It is preferably 99.9% by weight or less, more preferably 80% by weight or less, and further preferably 60% by weight or less. Moreover, it may be a consistent combination thereof.
  • the intake of isoflavone glycosides and / or isoflavones of aglycon and lactobionic acid in the composition according to this embodiment is not only the age and body weight of the subject, but also diseases, disorders, symptoms and symptoms (in the present specification, " " “Disease, disorder, symptom, symptom” may be collectively referred to as “disease, etc.”), isoflavone glycosides and / or, although it is appropriately set depending on the route of intake, intake schedule, formulation form, etc.
  • the skin is improved as long as the skin is improved more than the isoflavone glycosides and / or isoflavones aglycon alone and lactobionic acid alone in the subjects who ingested it. Not limited.
  • the total intake of isoflavone glycosides and / or isoflavones aglycones is preferably 20 mg or more, more preferably 25 mg or more per day in terms of aglycones. On the other hand, for example, it is less than 30 mg. Moreover, it may be a consistent combination thereof.
  • the aglycone conversion for example, in the case of isoflavone glycosides, the form in which the glycosides are desorbed is isoflavone aglycones. It is possible to calculate the amount of intake when converted to aglycone. In addition, the total amount of isoflavone aglycones can be treated as the intake of isoflavone aglycones.
  • the total daily intake of lactobionic acid is preferably 200 mg or more, more preferably 225 mg or more, still more preferably 250 mg or more, while preferably 1,000 mg or less, more preferably 800 mg or less. More preferably, it is 500 mg or less. Moreover, it may be a consistent combination thereof.
  • the ratio of the intake of isoflavone glycosides and / or isoflavones aglycone to lactobionic acid is preferably 1: 2 to 40, more preferably 1: 2 to 10, and further, as a total amount. It is preferably 1: 2 to 5.
  • soy isoflavone aglycone should not exceed 30 mg.
  • the total intake of isoflavone glycosides and / or isoflavone aglycones is preferably less than 30 mg per day in terms of isoflavone aglycones.
  • ingestion of isoflavone glycosides and / or isoflavone aglycones of less than 30 mg per day in terms of isoflavone aglycones may improve the skin. unknown.
  • the intake may be once a day or may be divided into a plurality of times a day. In addition, it may be taken once every few days or weeks, but it is preferable to take it every day.
  • the intake period may be, for example, 4 weeks or more, 8 weeks or more, or 12 weeks or more, 12 weeks or less, 8 weeks or less, or 4 weeks or less, in a consistent combination thereof. There may be. It is preferably 4 weeks or more, more preferably 8 weeks or more, still more preferably 12 weeks or more, while the upper limit is not particularly limited, for example, until the age of 100 years old, and until death. May be.
  • composition according to this embodiment can be used as a food or drink (including supplements).
  • a food or drink including supplements.
  • it can be used as a skin-improving food or drink containing isoflavone glycosides and / or isoflavone aglycones and lactobionic acid. It may also be used for purposes such as "cosmetics to eat” and "cosmetics to eat”.
  • isoflavones glycosides and / or isoflavones aglycon and lactobionic acid are used as raw materials for foods and drinks, in addition to general foods and drinks, foods for specified health use, dietary supplements, functional foods, foods for the sick , Food additives, etc. (These include beverages).
  • the form of the food or drink may be a form other than the plant itself or the animal itself containing the glycosyl of isoflavones and / or the aglycon and lactobionic acid of the isoflavones, and is used, for example, after adding an appropriate auxiliary agent.
  • the above foods and drinks can be mainly composed of water, proteins, sugars, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors and the like.
  • the protein include animal and vegetable proteins such as whole fat powder, defatted milk powder, partially defatted milk powder, casein, soybean protein, chicken egg protein, meat protein, hydrolysates thereof, butter and the like.
  • carbohydrates include sugars, processed starches (dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber and the like.
  • Examples of the lipid include lard, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, hydrogenated oil, and vegetable fats and oils such as ester exchange oil.
  • vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, and choline.
  • Folic acid and the like, and examples of minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium and milky minerals.
  • Examples of the organic acid include malic acid, citric acid, lactic acid, tartaric acid and the like. These components may be used in combination of two or more, and synthetic products and / or foods and drinks containing a large amount thereof may be used.
  • the above food and drink can be manufactured according to a conventional method.
  • the amount, method, and timing of blending of isoflavone glycosides and / or isoflavones aglycone and lactobionic acid in foods and drinks can be appropriately selected. Further, if necessary, it can be enclosed in an appropriate container such as a bottle, a bag, a can, a box, or a pack.
  • the content of isoflavone glycosides and / or isoflavones aglycone and lactobionic acid with respect to the total amount of the food and drink, the intake amount of the food and drink, and the intake schedule of the food and drink are based on the total amount of the composition according to this embodiment.
  • the description of the content of isoflavone glycosides and / or isoflavones aglycone and lactobionic acid, the intake amount of the composition according to this embodiment, and the intake schedule of the composition according to this embodiment is incorporated.
  • Glycosides of isoflavones and / or aglycones and lactobionic acids of isoflavones are used as materials for foods and drinks, and when they are used for skin improvement, they may be used as foods and drinks describing their uses, and they are recalled from their uses. It may be a food or drink that describes the intended use. Improving the moisturizing property of the skin and improving the skin barrier function are, for example, to keep the skin moisturized, to keep the skin moisturized, to make it difficult for the skin to escape, to make the skin difficult to dry, to relieve the dryness of the skin. It can be described as maintaining moisture, enhancing the barrier function of the skin, and enhancing the moisturizing power.
  • the improvement of the softness of the skin can be described as, for example, alleviating or suppressing the decrease in the elasticity of the skin, maintaining the elasticity of the skin, and the like.
  • the improvement of the texture can be described as, for example, adjusting the texture of the skin, suppressing the collapse of the texture, and making the texture finer.
  • the improvement of wrinkles can be described as, for example, eliminating wrinkles, eliminating wrinkles, producing swelling of the skin, relieving wrinkles, preventing the establishment of wrinkles, and eliminating old faces.
  • the improvement of anxiety about pores can be described as, for example, improving the opening of pores, tightening pores, and improving the conspicuity of pores.
  • the isoflavone glycoside and / or isoflavone aglycone contained in the composition according to this embodiment may be a composition containing isoflavone glycoside and / or isoflavone aglycone, for example, of isoflavones.
  • examples thereof include soybean germ extracts containing glycosides and / or aglycones of isoflavones. Therefore, the composition according to this embodiment may be a skin improving composition containing a glycoside of isoflavones and / or an aglycone of isoflavones and lactobionic acid.
  • composition according to this embodiment may be a skin improving composition containing a soybean germ extract containing isoflavone glycosides and / or isoflavone aglycones and lactobionic acid.
  • the glycoside of the isoflavones is a mixture of daidzin, glycitin, and genistin.
  • the isoflavone aglycone is a mixture of daidzein, glycitein, and genistein.
  • the soybean germ extract containing the isoflavone glycoside and / or the isoflavone aggrecon can be extracted from soybean and soybean germ (hypocotyl). Water, ethanol, or hydrous ethanol can be used for the extraction. Further, for example, it can be obtained as in the document "Development of a material containing plant polyphenols-its functionality and safety-" (published in 2007, published by CMC Publishing Co., Ltd.), and as in the examples described later. Obtainable. Further, if the isoflavone glycoside and / or the soybean germ extract containing isoflavone aglycone contains isoflavone glycoside and / or isoflavone aglycone, the component thereof is extracted or purified. It may be the one that has been done.
  • the soybean germ extract containing the isoflavone glycosides and / or isoflavone aglycones can be solidified by heat-drying treatment, spray-drying treatment, or freeze-drying treatment, if necessary. Both the heat drying treatment and the spray drying treatment can be performed using, for example, a spray drying device.
  • the freeze-drying process can be performed using a freeze-drying device. Further, after the heat-drying treatment, the spray-drying treatment, or the freeze-drying treatment, it may be subjected to a pulverization treatment, if necessary.
  • the lactobionic acid contained in the composition according to this embodiment may be a composition containing lactobionic acid, and examples thereof include fermented products containing lactobionic acid. Therefore, the composition according to this embodiment may be a skin improving composition containing a glycoside of isoflavones and / or a composition containing aglycone of isoflavones and lactobionic acid. In addition, the composition according to this embodiment may be a skin improving composition containing a glycoside of isoflavones and / or a fermented product containing aglycone of isoflavones and lactobionic acid.
  • the fermented product can be obtained by the method described above.
  • the fermented product containing lactobionic acid can be solidified by heat-drying treatment, spray-drying treatment, or freeze-drying treatment, if necessary. Both the heat drying treatment and the spray drying treatment can be performed using, for example, a spray drying device.
  • the freeze-drying process can be performed using a freeze-drying device. Further, after the heat-drying treatment, the spray-drying treatment, or the freeze-drying treatment, it may be subjected to a pulverization treatment, if necessary.
  • the composition according to this embodiment may be a skin improving composition containing a composition containing isoflavone glycosides and / or isoflavone aglycones and a composition containing lactobionic acid.
  • the composition according to this embodiment may be a skin improving composition containing a soybean germ extract containing isoflavone glycosides and / or isoflavone aglycones and a fermented product containing lactobionic acid.
  • the present disclosure can provide the following aspects. (1) Use of isoflavone glycosides and / or isoflavone aglycones and lactobionic acid for producing a skin improving composition. (2) Use of isoflavone glycosides and / or isoflavone aglycones and lactobionic acid for skin improvement. (3) Isoflavone glycosides and / or isoflavone aglycones and lactobionic acids for use in skin improvement. (4) (i) A method for improving the skin, which comprises the step of administering an effective amount of isoflavone glycosides and / or isoflavones aglycon and lactobionic acid to humans in need of improvement.
  • a skin improving composition comprising an effective amount of isoflavone glycosides and / or isoflavone aglycones and lactobionic acid, comprising the step of administering to a person in need of improvement. How to improve.
  • All of the above tablets have been treated with a tablet (300 mg / grain) having a diameter of 9 mm.
  • the tablets are based on maltodextrin, crystalline cellulose, fine silicon dioxide, calcium stearate.
  • 3 tablets daily were ingested for 12 weeks. Cheek keratin water content was measured before and 4, 8 and 12 weeks after ingestion of the tablets and evaluated in a single-blind parallel-group comparative study. The water content of the keratin was measured by measuring the capacitance on the skin surface using Corneometer (registered trademark) CM825 (Courage + Khazaka electronic GmbH).
  • ⁇ Preparation of lactobionic acid> 3 mL of medium containing 0.5% glucose, 0.5% yeast extract, 0.5% polypeptone, and 0.1% magnesium sulfate (pH 7.0) was dispensed into a test tube (18 mm ⁇ 200 mm) and sterilized at 121 ° C. for 20 minutes.
  • a platinum loop Gluconobacter cerinus NBRC 3267 strain was inoculated into the medium and cultured at 30 ° C. overnight with shaking (220 rpm).
  • 1 L of the medium having the above composition was dispensed, the above culture solution was inoculated into a 3 L Erlenmeyer flask sterilized at 121 ° C. for 20 minutes, and the cells were shake-cultured (220 rpm) at 30 ° C. for 3 days.
  • All of the above tablets have been treated with a tablet (300 mg / grain) having a diameter of 9 mm.
  • the tablets are based on maltodextrin, crystalline cellulose, fine silicon dioxide, calcium stearate.
  • one tablet (after breakfast) was taken daily for 12 weeks with a glass of water or lukewarm water.
  • the evaluation items were stratum corneum water content, percutaneous water evaporation (TEWL), skin viscoelasticity, and skin condition questionnaire.
  • the specified site was measured after acclimatization for 20 minutes or more in a constant temperature and humidity chamber with a temperature of 20 ⁇ 5 ° C and a humidity of 50 ⁇ 10% with the measurement site exposed. ..
  • the water content of the stratum corneum was measured by measuring the capacitance on the skin surface using Corneometer (registered trademark) CM825 (Courage + Khazaka electronic GmbH). The larger the value of the water content in the stratum corneum, the better.
  • TEWL transepidermal water loss
  • the skin viscoelasticity was measured using a Cutometer (registered trademark) MPA580 (Courage + Khazaka electronic GmbH, probe diameter 2 mm) for the left cheek.
  • MPA580 Cosmetic + Khazaka electronic GmbH, probe diameter 2 mm
  • the net elasticity (R5), total elasticity (R2), and return rate (R7) decrease with aging, and the larger the value, the better.
  • the unrecovered extensibility / regression ability (R1) is a value that increases with aging, and the smaller the value, the better.
  • the evaluation points are "1 point: I don't think at all”, “2 points: I don't think so much”, “3 points: I can't say either”, “4 points: I think a little”, “5 points: I strongly think” did. The smaller the score, the better for all items.
  • (a) shows the result of the left cheek and (b) shows the result of the left shin.
  • the value of transepidermal water loss (TEWL) (left shin) was smaller in the combination group than in the placebo group after ingestion. It was significantly smaller, especially 4 weeks after ingestion (Fig. 2).
  • the net elasticity (R5), total elasticity (R2), and return rate (R7) of the skin viscoelasticity (left cheek) were higher in the combination group than in the placebo group after ingestion. It was especially significant at 8 and 12 weeks after ingestion.
  • the values of unrecovered extensibility / involution (R1) of skin viscoelasticity (left cheek) were smaller in the combination group than in the placebo group after ingestion.
  • FIG. 3 shows the result of net elasticity (R5), and (b) shows the result of total elasticity (R2).
  • R5 shows the result of net elasticity
  • R7 shows the result of the return rate
  • R1 shows the result of the unrecovered extensibility / regression ability (R1).
  • the score for "sag under the eyes" was smaller in the combination group than in the placebo group after ingestion. It was significantly smaller, especially at 8 and 12 weeks after ingestion (Fig. 5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet au moins une technologie pour l'amélioration de la peau. À cet effet, l'invention porte sur une composition d'amélioration de la peau contenant de l'acide lactobionique et un aglycone d'une isoflavone et/ou un glycoside d'une isoflavone.
PCT/JP2021/043262 2020-11-26 2021-11-25 Composition d'amélioration de la peau WO2022114077A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022538321A JP7159511B1 (ja) 2020-11-26 2021-11-25 肌改善用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020196325 2020-11-26
JP2020-196325 2020-11-26

Publications (1)

Publication Number Publication Date
WO2022114077A1 true WO2022114077A1 (fr) 2022-06-02

Family

ID=81754318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/043262 WO2022114077A1 (fr) 2020-11-26 2021-11-25 Composition d'amélioration de la peau

Country Status (2)

Country Link
JP (1) JP7159511B1 (fr)
WO (1) WO2022114077A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020004568A1 (fr) * 2018-06-28 2020-01-02 アサヒグループホールディングス株式会社 Promoteur de production d'équol et composition alimentaire ou de boisson le comprenant pour favoriser la production d'équol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019129789A (ja) * 2018-02-01 2019-08-08 株式会社ノエビア 抗ニキビ用食品、髪質改善用食品又は化粧のり改善用食品
WO2020204568A1 (fr) 2019-04-01 2020-10-08 김관현 Moteur à turbine à déplacement positif
KR20230013255A (ko) * 2020-05-21 2023-01-26 주식회사 다이셀 폐경 후에 갱년기 장애를 가지지 않는 만 40세 이상의 여성을 위한 qol 개선용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020004568A1 (fr) * 2018-06-28 2020-01-02 アサヒグループホールディングス株式会社 Promoteur de production d'équol et composition alimentaire ou de boisson le comprenant pour favoriser la production d'équol

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Conference report of the 38th Annual Meeting of the Japanese Society of Aesthetic Dermatology", FRAGRANCE JOURNAL, vol. 48, no. 11, 15 November 2020 (2020-11-15), JP , pages 84 - 88, XP009537063, ISSN: 0288-9803 *
TAKASHI KIMURA: "Anti-aging effect of new functional sugar "lactobionic acid"", SHOKUHIN KOGYO - FOOD INDUSTRY, vol. 54, no. 22, 1 January 2011 (2011-01-01), JP , pages 76 - 81, XP009537059, ISSN: 0559-8990 *
TOMOKO UESHIMA: "The source of the power of soy isoflavones! "Equol + lactobionic acid" supplement essential for women's beauty and health", JP, pages 1 - 4, XP009537096, Retrieved from the Internet <URL:https://web.archive.org/web/20200524065048/https://binotane.com/products/bi-mono_002/> [retrieved on 20220113] *

Also Published As

Publication number Publication date
JPWO2022114077A1 (fr) 2022-06-02
JP7159511B1 (ja) 2022-10-24

Similar Documents

Publication Publication Date Title
KR102358623B1 (ko) 콜라겐 펩타이드를 포함하는 피부 개선용 식품 조성물
JP6980644B2 (ja) 女性特有の身体的及び／又は精神的不快症状の改善剤
KR102153414B1 (ko) 약콩 발효물을 포함하는 탈모 개선 및 발모 촉진용 조성물
JP2010178736A (ja) 肌美容改善剤、抗酸化剤、肌美容改善用組成物、又は美容用飲食品
CN110037113A (zh) 一种女士瘦身养颜奶粉
JP2002003390A (ja) 線維芽細胞増殖作用剤、美容用飲食品および皮膚化粧料
TWI586376B (zh) Skin improvement methods and methods to promote collagen production
EP1629723A1 (fr) Aliment fonctionnel et son utilisation
JP2001316240A (ja) コラーゲン産生促進剤、エストロゲン様作用剤、皮膚化粧料および美容食品
CN104822424A (zh) 局部施用类视黄醇化合物后增强皮肤耐受性的口服组合物
KR20170121532A (ko) 갱년기 증상 또는 골다공증 개선용 조성물
WO2022114077A1 (fr) Composition d&#39;amélioration de la peau
KR102437419B1 (ko) 숙취해소용 조성물
KR102300580B1 (ko) 뱅쇼 추출물을 포함하는 화장료 조성물
JP2012067082A (ja) 経口組成物
JP2007008902A (ja) 抗炎症剤、抗酸化剤及び美白剤、並びに皮膚化粧料及び飲食物
JP6141071B2 (ja) 肌水分量増加剤
JP7166500B1 (ja) イソフラボン吸収促進剤及び皮膚水分量低下抑制剤
KR20170133820A (ko) 갱년기 증상 또는 골다공증 개선용 조성물
JP2009161526A (ja) 治療剤
WO2006035700A1 (fr) Préparation contenant une proanthocyanidine et un sphingolipide
JP2003128569A (ja) 皮膚外用剤および飲食品
KR20180104960A (ko) 바나나, 체리 및 호두의 혼합 추출물을 포함하는 피부 노화 방지 또는 개선용 조성물
JP2013116887A (ja) 経口用育毛剤
JP2003128562A (ja) 皮膚外用剤および飲食品

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2022538321

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21898049

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21898049

Country of ref document: EP

Kind code of ref document: A1